Atlas Trials

PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment

Clinical trial NCT04634058 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04634058
Sponsor
Shanghai Zhongshan Hospital
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Cholangiocarcinoma, IntrahepaticPD-L1CTLA4
Start date
2021-03-26
Primary completion
2023-09-30
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.